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Previews
a significant 65% decrease in sedimentable A in theMetal Chelator Decreases
five CQ-treated mice, and two showed no measurableAlzheimer -Amyloid Plaques A in the pellet fraction and no detectable A pathology
by immunocytochemistry. The authors then examined
the effects of a higher dose (30 mg/kg/d) for 9 weeks
in older 21-month-old mice (n  20) as compared toTransgenic mice developing -amyloid (A) plaques
sham-fed mice (n 19). This resulted in a 41% decreaseare advancing experimental treatment strategies for
in levels of A in the brain pellet, and there was a de-Alzheimer’s disease. The metal chelator, clioquinol, is
crease in the immunohistochemical amyloid plaque sur-reported by Cherny et al. (2001) to reduce A plaques,
face area. The levels of soluble A increased by 52%.presumably by chelation of A-associated zinc and
Cerebral synaptophysin, GFAP, and APP levels werecopper. This and other recent A-modulating treat-
unchanged. The Cu and Zn levels were significantly in-ment approaches are discussed.
creased in the soluble cerebral fractions of the CQ-
treated mice but unchanged in the pellet. In the 21-
This month’s issue of Neuron contains a report of an
month-old animals, CQ did not have any appreciableinnovative approach to treating -amyloid (A) deposi-
effects on weight loss or mean survival, and a ratingtion in a transgenic mouse model of Alzheimer’s disease
scale of motor activity, alertness, and general health(AD). The report by Cherny and colleagues (Cherny et
indicated improvement in the CQ-treated mice as com-al., 2001 [this issue of Neuron]) builds on prior work by
pared to sham control mice.this group showing that both zinc and copper in vitro
These results are intriguing and suggest a possiblepotentiate A aggregation and neurotoxicity. They also
unique approach to treating A deposition. There arerecently reported that A can bind copper and zinc and
several other recently reported therapeutic approaches.may possess a superoxide dismutase activity in con-
These include A immunization (Schenk et al., 1999;verting O2 to H2O2. Other work has shown that copper
Janus et al., 2000; Morgan et al., 2000), - and -secre-and zinc are elevated in the neocortex in AD and are
tase inhibitors, modulators of inflammation (Lim et al.,particularly concentrated in senile plaques.
2000; Wyss-Coray et al. 2001), and cholesterol-loweringWith this in mind, Cherny et al. initially reported that
drugs (Fassbender et al., 2001). Some of these therapiesCu/Zn chelators solubilize A from postmortem AD brain
are directed against cellular A production and otherstissue. In the present report, they have extended these
against aggregated A plaques (see figure). Of these,studies to a transgenic mouse model, which develops
A immunotherapy has provided the most establishedA deposits (the Tg2576 mice carrying the Swedish fa-
and quantifiable improvements in behavior of treatedmilial AD mutation at APP670/671). The authors chose
mice, using tests such as the radial-arm water mazethe chelator clioquinol (CQ) based on its ability to cross
test of working memory (Morgan et al., 2000; Janus etthe blood-brain barrier. Initial in vitro studies showed
al., 2000). A potential worry about -secretase inhibitionthat CQ solubilized A1-40 aggregates induced by either
was that it could inhibit Notch signaling, which couldZn2 or Cu2 but was ineffective at low pH (5.5), which
affect the bone marrow; however, recent evidence hasinduces -pleat formation of A. CQ was also effective
shown that the two effects can be dissociated with novelin liberating A from postmortem brain samples of AD
inhibitors (Petit et al., 2001). The development of -secre-patients. They then tested CQ at 20 mg/kg by gavage
for 12 weeks in 12-month-old Tg2576 mice. There was tase inhibitors appears particularly promising since
Therapeutic Targets for Modulating A in AD
The presumptive sites of action of therapeutic
targets for AD aimed at A. These targets
are generally believed to directly affect either
intracellular neuronal A generation or disso-
lution of extracellular A plaques. The biolog-
ical mechanism linking neuronal A, A pro-
tofibrils, and A plaques and their more
precise role in pathogenesis remains un-
certain.
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ties precede A plaque deposition in AD transgenic 4, 231–232.
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lating A may prove to be important for the pathogenic Petit, A., Bihel, F., da Costa, C.A., Pourquie, O., Checler, F., and
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It may therefore be important to block the accumulation Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido,
of both intracellular and extracellular A. T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999).
Nature 400, 173–177.Now that the AD field is entering a new era of experi-
mental therapeutics, it is imperative to rigorously extend Selkoe, D.J. (2001). Physiol. Rev. 81, 741–766.
animal studies either prior to or in parallel to entering Wilson, C.A., Doms, R.W., and Lee, V.M. (1999). J. Neuropathol. Exp.
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egies studied in transgenic mice that exhibit extensive Wyss-Coray, T., Lin, C., Yan, F., Yu, G.Q., Rohde, M., McConlogue,
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clude plaques not being the optimal marker of therapeu-
tic success and the possibility that treatment-associ-
ated neurotoxicity may nonspecifically decrease A Do Schwann Cells Stop, DR(o)P2,plaques. In this regard, the major concern about CQ as a
and Roll?treatment for AD is its association with subacute myelo-
optic neuropathy (SMON), which was largely confined
to Japan. Recent experimental work with CQ showed
Dystrophin-dystroglycan complexes in Schwann cellsthat it depletes brain and serum levels of vitamin B12.
may play a role in both signaling and structural interac-Since vitamin B12 deficiency is associated with both
tions between the extracellular matrix and the cyto-myelopathy and optic neuropathy, it is plausible al-
skeleton. Sherman et al. (2001) show that a new com-though unproven that CQ could induce SMON by this
plex containing dystrophin-related protein 2 (DRP2)mechanism. Nevertheless, the authors indicate that clin-
and periaxin plays a role in Schwann cell-basal laminaical trials of CQ in combination with vitamin B12 have
interactions and PNS myelination.completed phase one and have entered phase two with
reportedly no adverse effects having been encountered.
This is an exciting time in Alzheimer’s disease research Myelin is a lipid-rich organelle that determines saltatory
since therapies that can directly address the -amyloid conduction of impulses, as well as important physical
hypothesis are now available. A number of these have properties, along axons (Arroyo and Scherer, 2000).
reached the clinic, including A immunotherapy, -secre- Schwann cells synthesize myelin in peripheral nerves,
tase inhibitors, anti-inflammatory agents, cholesterol- following a strict blueprint. First, Schwann cells must
lowering drugs, and now clioquinol. We eagerly await achieve a one-to-one relationship with a large caliber
the outcome of these studies with the hope that we will axon, organize a basal lamina, and then advance a lip
have therapies directly aimed at the underlying disease of membrane in an inward spiral, encircling the axon as
process. many as 50–100 times. Afterward, the extracellular and
intracellular spaces are compacted from the majority of
the membrane to create compact myelin and variousGunnar K. Gouras and M. Flint Beal
cytoplasmic domains. The transition from a prolongedDepartment of Neurology and Neuroscience
bipolar cell to a precisely ordered cylinder containing aWeill Medical College of Cornell University
compact myelin sheath represents a complex architec-New York, New York 10021
tural problem.
Myelin-forming Schwann cells have solved this prob-
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